|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM371589916 |
003 |
DE-627 |
005 |
20240712233535.0 |
007 |
cr uuu---uuuuu |
008 |
240427s2024 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1002/adma.202313212
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1468.xml
|
035 |
|
|
|a (DE-627)NLM371589916
|
035 |
|
|
|a (NLM)38670140
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Li, Zongheng
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Double-Layered Hollow Mesoporous Cuprous Oxide Nanoparticles for Double Drug Sequential Therapy of Tumors
|
264 |
|
1 |
|c 2024
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 12.07.2024
|
500 |
|
|
|a Date Revised 12.07.2024
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
520 |
|
|
|a Cancer stem cells (CSCs) are one of the determinants of tumor heterogeneity and are characterized by self-renewal, high tumorigenicity, invasiveness, and resistance to various therapies. To overcome the resistance of traditional tumor therapies resulting from CSCs, a strategy of double drug sequential therapy (DDST) for CSC-enriched tumors is proposed in this study and is realized utilizing the developed double-layered hollow mesoporous cuprous oxide nanoparticles (DL-HMCONs). The high drug-loading contents of camptothecin (CPT) and all-trans retinoic acid (ATRA) demonstrate that the DL-HMCON can be used as a generic drug delivery system. ATRA and CPT can be sequentially loaded in and released from CPT3ATRA3@DL-HMCON@HA. The DDST mechanisms of CPT3@ATRA3@DL-HMCON@HA for CSC-containing tumors are demonstrated as follows: 1) the first release of ATRA from the outer layer induces differentiation from CSCs with high drug resistance to non-CSCs with low drug resistance; 2) the second release of CPT from the inner layer causes apoptosis of non-CSCs; and 3) the third release of Cu+ from DL-HMCON itself triggers the Fenton-like reaction and glutathione depletion, resulting in ferroptosis of non-CSCs. This CPT3@ATRA3@DL-HMCON@HA is verified to possess high DDST efficacy for CSC-enriched tumors with high biosafety
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a CSC‐enriched tumors
|
650 |
|
4 |
|a cancer stem cells (CSCs)
|
650 |
|
4 |
|a double drug sequential therapy (DDST)
|
650 |
|
4 |
|a double layered hollow mesoporous cuprous oxide nanoparticles (DL‐HMCONs)
|
650 |
|
4 |
|a generic drug delivery system (DDS)
|
650 |
|
7 |
|a Camptothecin
|2 NLM
|
650 |
|
7 |
|a XT3Z54Z28A
|2 NLM
|
650 |
|
7 |
|a Copper
|2 NLM
|
650 |
|
7 |
|a 789U1901C5
|2 NLM
|
650 |
|
7 |
|a cuprous oxide
|2 NLM
|
650 |
|
7 |
|a T8BEA5064F
|2 NLM
|
650 |
|
7 |
|a Tretinoin
|2 NLM
|
650 |
|
7 |
|a 5688UTC01R
|2 NLM
|
650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
650 |
|
7 |
|a Drug Carriers
|2 NLM
|
700 |
1 |
|
|a Yang, Jing
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ren, Bin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fan, Qingdeng
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Huang, Lin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Guo, Shuai
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhou, RuiLong
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Sijin
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Feng, Jie
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Yan, Chenggong
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shen, Zheyu
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 28 vom: 10. Juli, Seite e2313212
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:28
|g day:10
|g month:07
|g pages:e2313212
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202313212
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 36
|j 2024
|e 28
|b 10
|c 07
|h e2313212
|